Guushii Madhavan: Ka adkaanta Glioma-ga Maskaxda iyadoo la adeegsanayo Bioocus B7H3 CAR-T Therapy

Taariikhda Bukaanka

Madhavan waxaa laga helay cudurka glioma maskaxda, oo ah buro halis ah oo loo yaqaan duullaankeeda iyo saadaalinteeda liidata. Markii uu jiray 58 sano, ka dib markii daaweyntii caadiga ahayd oo ay ku jiraan qalliin iyo shucaacu ay ku guuldareysteen, wuxuu u jeestay Bioocus si uu u helo fursado horumarsan. Markii loo gudbiyay Isbitaalka Tianjin Tumor Hospital Konggang, wuxuu iska diiwaan geliyay barnaamijkayaga B7H3 CAR-T ee lambarka daaweynta P001. B7H3 si weyn ayaa looga muujiyaa unugyada glioma, taasoo ka dhigaysa bartilmaameed ku habboon unugyada T ee la farsameeyay ee lagu maamulo dareeraha cerebrospinal (CSF) si ay si toos ah u weeraraan burooyinka.

Safarka Daaweynta

Daawaynta Madhavan waxay ku lug lahayd in unugyada CAR-T ee iswada lagu shubo CSF, iyadoo lala socdo iyada oo loo marayo falanqaynta taxanaha ah ee CSF laga bilaabo Maalinta 2aad (D2) ilaa Maalinta 28aad (D28).

• D2 (Ogosto 8, 2025):Joogitaan xooggan oo bilow ah oo leh B7H3 CAR-T oo ah 54.44% unugyada CD3+ T.
• D4 (Ogosto 11, 2025):52%, taasoo ka tarjumaysa dhaqdhaqaaqyadii hore.
• D7 (Ogosto 14, 2025):Waxay gaartay 59.51%.
• D10 (Ogosto 17, 2025):12%.
• D14 (Ogosto 21, 2025):19%.
• D21 (Ogosto 28, 2025):Ugu sarreysay 89.69%, taasoo muujinaysa koror aad u wanaagsan.
• D28 (Sebtembar 6, 2025):Waxaa lagu dejiyay 13.58% unugyada CD3+ T, iyadoo 11.90% ay ku jiraan CD4+ iyo 14.28% ay ku jiraan qaybaha CD8+. Guud ahaan, unugyada CD3+ T waxay ku badan yihiin 95.34%, iyadoo CD8+ oo sarreeya (66.74%) uu muujinayo sunta sunta ah ee xooggan.

Garaafyada ballaarinta waxay muujiyeen adkeysi CAR-T oo isbeddelaya laakiin guud ahaan xooggan, oo lagama maarmaan u ah xakamaynta joogtada ah ee burooyinka CNS.

Natiijooyinka Heerka Sare ah

Fidinta ugu sarreysa ee D21 waxay la xiriirtay yaraanta burooyinka ee MRI, taasoo keentay jawaab qayb ah oo D28 ah iyo horumar joogto ah. Bixintan gudaha ah waxay yareysaa waxyeellooyinka nidaamka iyadoo la kordhinayo waxtarka ka dhanka ah gliomas, iyadoo xogteennu ay muujineyso badbaado horumar la'aan ah. Madhavan waxay soo sheegtay calaamado la maareyn karo oo aan lahayn sunta neerfaha ee daran.